Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...

Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

Stock analysts at Leerink Partners started coverage on shares of CorMedix (NASDAQ:CRMD – Get Free Report) in a report ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ...

In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price ...

Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight ...

Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida. Dr. Brady’s ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Align Tech (ALGN – Research Report) today and set a price target of $275.00.